Can-Fite BioPharma (CANF) Long-Term Deferred Tax (2019 - 2025)
Can-Fite BioPharma's (CANF) quarterly Long-Term Deferred Tax came in at $34.1 million in Q4 2025, up 21.5% YoY from $28.1 million in Q4 2024, and up 21.5% on a QoQ basis from $28.1 million in Q4 2024.
Can-Fite BioPharma (CANF) Long-Term Deferred Tax (2019 - 2025) Analysis & Trends
Can-Fite BioPharma (CANF) has 7 years of Long-Term Deferred Tax data on file, last reported at $34.1 million in Q4 2025.
- Quarterly Long-Term Deferred Tax rose 21.5% year-over-year to $34.1 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $34.1 million (up 21.5% YoY) and the FY2025 annual result came in at $34.1 million, up 21.5% from the prior year.
- Long-Term Deferred Tax advanced to $34.1 million in Q4 2025, from $28.1 million in the prior quarter.
- In the past five years, Long-Term Deferred Tax ranged from a high of $34.1 million in Q4 2025 to a low of $25.1 million in Q4 2022.
- A 5-year average of $28.3 million and a median of $28.1 million in 2024 frame the typical range for Long-Term Deferred Tax.
- Annual changes were most pronounced in 2021 — Long-Term Deferred Tax retreated 20.23% — and 2025, when it grew 21.5%.
- Tracing CANF's Long-Term Deferred Tax over 5 years: stood at $28.6 million in 2021, then fell by 12.21% to $25.1 million in 2022, then advanced by 1.87% to $25.6 million in 2023, then climbed by 9.58% to $28.1 million in 2024, then gained by 21.5% to $34.1 million in 2025.
- The last three Long-Term Deferred Tax figures came in at $34.1 million (Q4 2025), $28.1 million (Q4 2024), and $25.6 million (Q4 2023), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Can-Fite BioPharma | 2.76 Mn | -8.79 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 34.09 Mn |
| Dec 31, 2024 | 28.06 Mn |
| Dec 31, 2023 | 25.61 Mn |
| Dec 31, 2022 | 25.14 Mn |
| Dec 31, 2021 | 28.63 Mn |
| Dec 31, 2020 | 35.89 Mn |
| Dec 31, 2019 | 29.53 Mn |